The title of Dr. Mehling’s presentation is “Umbilical Cord Blood Stem Cell Therapy for Spinal Cord Injury.”
Spinal cord injury (SCI) is a common type of severe trauma often resulting in a permanent neurologic deficit. The current retrospective cohort study is aimed to analyze the muscle, nerve, urinary, and gastrointestinal function in SCI subjects treated with either human Umbilical Cord Blood Mononuclear Cells (hUCMNCs) or conventional therapy. Thirty patients with spinal cord injury were randomly selected from seventy treated with hUCMNCs between March 2009 and March 2012. Another thirty patients with SCI, who received only traditional therapy and no stem cell therapy, were included as the control group.
This study was approved by an Institutional Review Board of the Wright State University (Office of Research and Sponsored Programs. SC# 5488, “Spinal Cord Injury Stem Cell Therapy”).
A significantly higher proportion of subjects in the hUCMNCs therapy group showed improved function in pain and temperature sensation, lower limb muscle strength, bladder function, and gastrointestinal function compared to a conventional therapy group.
More information about the summit can be found here: https://www.worldbrainmapping.org/G20-World-Brain-Mapping-Therapeutics-Initiative/
To view the Program please click below:
